T1	Participants 45 78	patients with chronic hepatitis C
T2	Participants 300 333	patients with chronic hepatitis C
T3	Participants 410 418	PATIENTS
T4	Participants 524 557	patients with chronic hepatitis C
T5	Participants 969 1001	control and the amantadine group
T6	Participants 1012 1058	the control group but not the amantadine group
T7	Participants 1354 1367	placebo group
T8	Participants 1187 1224	nonresponders in the amantadine group
